Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors.

ABSTRACT:

Introduction

Neuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely. As described in the literature, in some selected cases, peptide receptor radionuclide therapy (PRRT) may be used as a first-line/neoadjuvant therapy that allows further successful surgery. Such treatment may enable a reduction of total tumor burden or allow a radical treatment which improves the final outcomes.

Aim

This study aims to assess whether neoadjuvant PRRT could be a treatment option for patients with initially unresectable NETs.

Methods

Among the group of 114 patients treated with PRRT between the years 2005 and 2020, in 32 cases, it

SUBMITTER: Opalinska M 

PROVIDER: S-EPMC8633407 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature